anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Angiogenesis is considered one of the hallmarks of cancer, assisting tumor progression and metastasis. The mesoionic compound, MI-D, can induce cell death and provoke cytoskeletal and metabolic changes in cancer cells. Using in vitro and in vivo models, this study aimed to evaluate the effects of MI-D on the viability of human endothelial cells (EC) and its ability to inhibit tumor-induced angiogenesis induced by tumoral cells. For in vitro analysis, colon carcinoma (HT29) and endothelial (EA.hy926) cells were used as the tumoral and angiogenesis models, respectively. To evaluate cytotoxicity, methylene blue viability stain and annexin-V/7AAD tests were performed with both cell types. For the angiogenesis experiments, scratch wound healing and capillary tube-like formation assays were performed with the EC. The in vivo tests were performed with the chorioallantoic membrane (HET-CAM) methodology, wherein gelatin sponge implants containing MI-D (5, 25, and 50 μM), HT29 cells, or both were grafted in the CAM. Our data showed that MI-D induced apoptosis in both endothelial and colon carcinoma cells, with a strong cytotoxic effect on the tumoral lineage. The drug inhibited the EC's migration and capillary-like structure formation in vitro. In the HET-CAM assays, MI-D reduced the number of blood vessels in the membrane when grafted alone and accompanied by tumor cells. In this study, MI-D interfered in important steps of angiogenesis, such as maintenance of endothelial cell viability, migration, formation of capillary-like structures, as well tumor-induced neovascularization, reinforcing the hypothesis that MI-D might act as an inhibitor of angiogenesis, and a potential antitumor agent.
PROBLEM TO BE SOLVED: To obtain the subject new compounds, capable of inducing the expression of a protein for inhibiting cyclin-dependent kinases independently of a tumor suppressor gene product p53 by culturing a compound microorganism belonging to the genus Pseudomonas in a culture medium. SOLUTION: The new compounds are FR190895 (C23 H24 N2 O7 having 102-105 deg.C melting point), FR190872 (C23 H24 N2 O6 having 104-107 deg.C melting point) and FR190873 (C23 H24 N2 O6 ). The compounds are obtained by culturing a microoganisms, belonging to the genus Pseudomonas and capable of producing at least one compound of the FR190895, FR190872 and FR190873, etc., [e.g. Pseudomonas chlororaphis No.4306 strain (FERM BP-5232)] in a nutrient culture medium and collecting the resultant product from the obtained cultured product. The compounds are readily soluble in methanol, chloroform and dimethyl sulfoxide and insoluble in water and capable of manifesting the positivity to the cerium sulfate and iodine vapor reactions and the negativity to the ninhydrin, ferric chloride and Molisch reactions. All of the compounds are a light-yellow powder.
The developed long and short aptamer sequences can be used as high affinity and specificity tools to analyze the drug Dabigatran etexilate for therapeutic drug monitoring, pharmacokinetic and naturalization studies. Using the technique by performing several rounds of selection and enrichment with a randomized 60-mer DNA library, a number of specific aptamer sequences were successfully selected for Dabigatran etexilate. We evaluated the binding affinity and specificity of the generated aptamers showing dissociation constants (k d ) ranging from 47-312 nM and very weak or no cross-reactivity to other analytes. Complimentary sequences labelled with a fluorophore and a quencher was used for mapping the binding region within the aptamer by monitoring the change in the fluorescence signal. A truncated sequence was used to construct a turn-on fluorescence sensor. The application of the long and short sequences in electrochemical and fluorescence sensors, respectively implying the usefulness of these aptamers in Dabigatran etexilate diagnostics applications and has unique potential of clinical uses in the near future.
Infertility is a common problem. Assisted reproductive techniques (ART) increases the chance of getting pregnant by couples undergoing such treatment. Unfortunately, the numer of live births after ART remains still low. Over the past three decades, physicians have tried to improve infertility diagnosis and increase its successful treatment. An effort aimed at increasing effectivenes of diagnosis resulted in hypothesis that one of probable reasons of infertility may be the occurrence of microclots, which worsen implantation and embryos development. There are currently no published studies describing the effects of different ovarian hyperstimulation protocols on hemostasis (coagulation and fibrinolysis).

The parameters of thrombin generation and efficiency of fibrinolysis will be evaluated in women qualified for ovarian hyperstimulation. The study may improve the effectiveness of ART.
BACKGROUND: Policymakers use clinical and cost-effectiveness evidence to support decisions about health service commissioning. In England, the National Institute for Health and Care Excellence (NICE) recommend that in cost-effectiveness analyses "effectiveness" is measured as quality-adjusted life years (QALYs), derived from health utility values. The impact of perinatal death (stillbirth/neonatal death) on parents' health utility is currently unknown. This knowledge would improve the robustness of cost-effectiveness evidence for policymakers.
OBJECTIVE: This study aimed to estimate the impact of perinatal death on parents' health utility.
METHODS: An online survey conducted with mothers and fathers in England who experienced a perinatal death. Participants reported how long ago their baby died and whether they/their partner subsequently became pregnant again. They were asked to rate their health on the EQ-5D-5L instrument (generic health measure). EQ-5D-5L responses were used to calculate health utility values. These were compared with age-matched values for the general population to estimate a utility shortfall (i.e. health loss) associated with perinatal death.
RESULTS: There were 256 survey respondents with a median age of 40 years (IQR 26-40). Median time since death was 27 months (IQR 8-71). The mean utility value of the sample was 0.774 (95% CI 0.752-0.796). Utility values in the sample were 13% lower than general population values (p < 0.05). Over 10 years, this equated to a loss of 1.1 QALYs. This reduction in health utility was driven by anxiety and depression.
CONCLUSIONS: Perinatal death has important and long-lasting health impacts on parents. Mental health support following perinatal bereavement is especially important.
This study will recruit up to 40 patients planned to receive curative (chemo) radiotherapy for (head and neck squamous cell carcinoma) HNSCC with primary tumor and/or involved lymph node suitable for repeat biopsy in clinic. After being informed about the study and potential risks, patients giving written informed consent will be randomized to receive conventional radiotherapy (single integrated boost or conventional two-phase at clinician discretion) or reversed two-phase treatment with delayed irradiation of elective nodal volumes. Patients will not be informed of their randomization result.

Patients in both arms will undergo a baseline functional magnetic resonance imaging (fMRI) scan and within 72 hours, when possible, a biopsy of the primary tumor +/- lymph node will be performed in an out-patient clinic. If a suitable biopsy has been recently performed as part of diagnostic work up the baseline biopsy on study will be omitted when possible. In week 2 of radiotherapy, patients will have a second fMRI scan and a paired biopsy within 72 hours of the scan, where possible. A further optional biopsy and paired fMRI scan in week 4 will be considered for patients who are tolerating therapy without \>G1 toxicities. 16-24 hours prior to each biopsy the patient will take oral pimonidazole. At the time of each biopsy a blood draw will be performed.
The invention relates to a method of obtaining keratin products (soluble keratin and insoluble keratin microfibres) from livestock waste, such as feathers, hair, hide, hooves and horns.  The inventive method, which is performed under cold conditions, comprises a series of steps involving crushing, hydrolysis of the waste and oxidation, in order to obtain both of the aforementioned products, followed by specific steps for each of said products.  The subsequent steps used to obtain soluble keratin comprise adjustment to neutral pH, ultrafiltration, washing and drying by means of spraying or lyophilisation.  The soluble keratin thus obtained has characteristics rendering same suitable for use in the cosmetic industry and the human and animal food industry.  The earlier steps used to obtain insoluble keratin microfibres comprise adjustment to acid pH, decantation, adjustment to neutral pH and washing, another decantation step, another washing step, additional decantation and a polymerisation phase such as to obtain larger keratin fibres with greater polymerisation.  The insoluble keratin microfibres thus obtained have increased elasticity and strength properties, thereby rendering same suitable for use in the textile industry and in the production of polymers, paper and biomaterials.
Liver fibrosis is a hallmark of chronic liver disease which could lead to liver cirrhosis or liver cancer. However, there is currently lack of a direct treatment for liver fibrosis. Boiling histotripsy (BH) is an emerging non-invasive high-intensity focused ultrasound technique that can be employed to mechanically destruct solid tumour at the focus via acoustic cavitation without significant adverse effect on surrounding tissue. Here, we investigated whether BH can mechanically fractionate liver fibrotic tissue thereby exhibiting an anti-fibrotic effect in an animal model of liver fibrosis. BH-treated penumbra and its identical lobe showed reduced liver fibrosis, accompanied by increased hepatocyte specific marker expression, compared to the BH-untreated lobe. Furthermore, BH treatment improved serological liver function markers without notable adverse effects. The ability of BH to reduce fibrosis and promote liver regeneration in liver fibrotic tissue suggests that BH could potentially be an effective and reliable therapeutic approach against liver fibrosis.
The invention relates to a method for the production of an adhesive and an adhesive kit for joining similar or different metal surfaces or ceramics, especially in the field of biomedicine. The objective of the invention is to avoid polymerization-linked by-products and disadvantageous effects, in addition to enabling a temporary biocompatible bond between metal and metal or metal and ceramics. The inventive method consist in using a monomer-free polymethylmethacrylate which is mixed with a suitable, non-toxic solvent and a bioactive vitreous-crystalline material with a particle size ranging from 0.05-20mu, consisting of 15-45 wt. % CaO, 40-45 wt. % P<SUB>2</SUB>O<SUB>5</SUB>, 10-40 wt. % ZrO<SUB>2 </SUB>and 0.7-3.5 wt. % fluoride, having apatite and calcium zircon phosphate as main crystal phases and a glass phase as an auxiliary component until a flowable mixture is obtained. The invention also relates to an adhesive kit consisting of said components. Sufficient amounts of resistance are obtained for a temporary bond, enabling the bond to be neutralized when desired.
FIELD: medicine. SUBSTANCE: method involves applying lys-plasminogen produced by proteolytically splitting glu-plasminogen that protects tissues injured in ischemic state. Lys-plasminogen is applied for treating patients both during reperfusion and after it is over. Lys-plasminogen is optionally administered in combination with thrombolytic therapy when plasminogen tissue activator is applied. EFFECT: enhanced effectiveness of treatment; accelerated anastomosis adhesion; stable hemodynamic state. 33 cl, 4 dwg, 2 tbl
PURPOSE: To provide a kit capable of easily producing a radioactive halogenated arom. diagnostic agent. CONSTITUTION: This kit includes bromine or iodine substd. arom. or heteroaromatic compd., water-soluble acid, copper salt and, in some cases, a medicinally permissible compounded liquid and/or auxiliary substance and further >=1 kinds of reducing agents stable within an acidic medium as well as a use instruction manual which instructs to produce chlorinated, brominated, radioactive-brominated, iodinated and/or radioactive-iodinated arom. compounds by reacting halogenated or diazonium-subtd., compds. corresponding to these compds. with a water-soluble chloride, bromide, radioactive bromide, iodide or radioactive iodide in the presence of a water soluble acid and copper ions as a catalyst and >=1 reducing agents stable in the acidic medium in the amt. exceeding the amt. of the catalyst.
Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
The present invention discloses ointment for treating spinal hyperosteogeny, which is prepared from sea-horse, pearls, edible tulips, eupolyphaga, large leaf gentian, chinaberry seeds, giant typhonium rhizomes, safflowers from Sichuan of China, Chiese eaglewood wood, corydalis tubers, akebia stems, doubleteeth pubesscent angelica roots, common monkshood mother roots, kusnezoff monkshood roots, angelica, dragon blood, pangolin scale, panax notoginseng, rhubarb, southern star, rehmannia roots, amur cork-tree, liquorice, borneol, musk, rosin dust and hot pepper dust. The ointment has strong penetrability, obvious effect and good therapeutic efficacy. The ointment is pasted on afflicted parts. The ointment is changed for one time at morning or in evening every day. Six days are a course of treatment. For patients with spinal hyperosteogeny, the patients with mild symptoms can be cured in one to two courses of treatment, and the patients with serious symptoms can be cured in two to three courses of treatment.
BACKGROUND AND AIMS: Several factors, such as hypertension and diabetes mellitus, are known to influence the course of coronavirus disease 2019 (COVID-19). However, there is currently little information on genetic markers that influence the severity of COVID-19. In this study, we specifically investigated the single nucleotide polymorphism (SNP) rs4986790 in the TLR4 gene to identify a universal marker for preclinical prediction of COVID-19 disease progression.
METHODS: We analyzed the influence of demographics, pre-existing conditions, inflammatory parameters at the time of hospitalization, and TLR4 rs4986790 genotype on the outcome of COVID-19 in a comprehensive cohort (N = 1570). We performed multivariable analysis to investigate the impact of each factor.
RESULTS: We confirmed that younger patient age and absence of pre-existing conditions were protective factors against disease progression. Furthermore, when comparing patients with mild SARS-CoV-2 infection with patients who required hospitalization or intensive care or even died due to COVID-19, the AG/GG genotype of TLR4 rs4986790 was found to be a protective factor against COVID-19 disease progression (OR: 0.51, 95% CI: 0.34 - 0.77, p = 0.001). In addition, we demonstrated that low levels of interleukin-6 (IL-6) and procalcitonin (PCT) had a favorable effect on COVID-19 disease severity. In the subsequent multivariable analysis, we confirmed the absence of cardiovascular disease, low levels of IL-6 and PCT, and TLR4 rs4986790 AG/GG genotypes as independent predictors of potential hospitalization and reduction of severe or fatal disease course.
CONCLUSION: In this study, we identified an additional genetic factor that may serve as an invariant predictor of COVID-19 outcome. The TLR4 rs4986790 AG/GG genotype reduced by half the risk of COVID-19 patients requiring hospitalization, intensive care or to have a fatal outcome. In addition, we were able to confirm the influence of previously known factors such as pre-existing conditions and inflammatory markers upon the onset of disease on the course of COVID-19. Based on these observations, we hereby provide another prognostic biomarker that could be used in routine diagnostics as a predictive factor for the severity of COVID-19 prior to SARS-CoV-2 infection.
Objective: To introduce the method of using anal fistula endoscope to treat chronic sinus tract leakage at rectal anastomosis site. Methods: We used anal fistula endoscopy to treat a patient with chronic sinus tract leakage after radical resection of rectal cancer, mainly including the following 5 steps: (1) establishing a water injection circulation system through the anus; (2) scraping off purulent coating and mucosa on the surface of the sinus tract with the brush; (3) hemostasis and removal of necrotic tissue with electrocoagulation rods; (4) filling the sinus tract with bioprotein gel; (5) compressing the sinus tract with transanal drainage tube. Results: The patient is a 70 year old male with rectal cancer. After undergoing 3D laparoscopic assisted radical resection of rectal cancer via abdominal anterior resection (Dixon's procedure) and diverting ileostomy surgery for more than 3 months, leakage of the rectal anastomosis was found through colonoscopy and anal iodine water contrast imaging .The patient started eating and flowing juice 6 hours after surgery, got out of bed 24 hours after surgery, and was discharged 48 hours after the removal of the anal canal. Three months after surgery, colonoscopy and transanal iodine hydrography showed that the sinus repair was intact. The diverting ileostomy was reduced 4 months after surgery. Conclusion: Anal fistula endoscope is safe and feasible for the treatment of chronic sinus tract anastomotic leakage in selected patients.
In this single centre, prospective, parallel group, cohort study, patients meeting the eligibility criteria are recruited at the department of surgery at Ersta hospital, Stockholm, Sweden. Patients with obesity and type 2 diabetes (T2D) are matched for age and sex with the group of patients with obesity without T2D. During the study the participants attend five study visits: at baseline, at the morning of surgery (after two weeks of low calory diet), 6 weeks, 1 year and 2 years after surgery. At each study visit a nurse records blood pressure, weight, height, and waist/hip circumferences. In addition, the nurse recalls the medical history and any medication use including contraceptive hormones and analgesics. Fat mass is determined using bioelectric impedance. Venous blood samples are collected with the patients in the supine position after overnight fasting and at least 20 minutes of rest. For later analyses, 25 mL of blood is collected in citrate tubes and centrifuged for 20 min at 2000 x g in room temperature. Plasma aliquots are subsequently stored at minus 80 degrees Celsius. Blood test regarding values at baseline (not the primary outcome variables) will be analysed at the local hospital laboratory. Examples of those basic variables are concentrations of glucose, insulin, blood cell counts and lipids.
The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
Continuous renal replacement therapy (CRRT) is an important support treatment technique for critically ill patients. Anticoagulation is a crucial part for CRRT. High bleeding risk, hypercoagulability, liver failure, and tissue hypoperfusion are very common in critically ill patients. Patients with these conditions, neonate/infant patients, and old patients need special considerations on clearance of anticoagulant and the efficacy and safety of anticoagulation for CRRT. Therefore, bleeding risk, coagulation status, metabolism characteristics of anticoagulation drug, and treatment needs should be considered when tailored anticoagulation strategies are chosen for CRRT in these patients. Additionally, closely monitoring of the relevant indicators and side effects are needed, and dosage and mode of different anticoagulants should be adjusted in a timely manner.
PROBLEM TO BE SOLVED: To and obtain a medicinal composition effective in treating diseases causing acute and/or chronic respiratory distress by increase intracellular synthesis of glutathione by using a specific non-cystine as an active ingredient. SOLUTION: This medicinal composition contains a glutathione ester in an amount enough to increase intracellular glutathione level of at least lung cell. Methyl ester, ethyl ester or isopropyl ester is preferably used as the glutathione ester. L-2-oxothiazolidin-4carboxylate can be exemplified in addition to the glutathione ester as the non-cystine substrate. The medicinal composition can parenterally or enterally be administered. The composition is effective for patients of systemic cystic fibrosis, patients having emphysema, patients, etc., of cataplectic pulmonary fibrosis.
BACKGROUND: Ferroptosis, a form of regulated cell death (RCD) that relies on excessive reactive oxygen species (ROS) generation, Fe2+accumulation, abnormal lipid metabolism and is involved in various organ ischemia/reperfusion (I/R) injury, expecially in myocardium. Mitochondria are the powerhouses of eukaryotic cells and essential in regulating multiple RCD. However, the links between mitochondria and ferroptosis are still poorly understood. Salidroside (Sal), a natural phenylpropanoid glycoside isolated from Rhodiola rosea, has mult-bioactivities. However, the effects and mechanism in alleviating ferroptosis caused by myocardial I/R injury remains unclear.
PURPOSE: This study aimed to investigate whether pretreated with Sal could protect the myocardium against I/R damage and the underlying mechanisms. In particular, the relationship between Sal pretreatment, AMPKα2 activity, mitochondria and ROS generation was explored.
STUDY DESIGN AND METHODS: Firstly, A/R or I/R injury models were employed in H9c2 cells and Sprague-Dawley rats. And then the anti-ferroptotic effects and mechanism of Sal pretreatment was detected using multi-relevant indexes in H9c2 cells. Further, how does Sal pretreatment in AMPKα2 phosphorylation was explored. Finally, these results were validated by I/R injury in rats.
RESULTS: Similar to Ferrostatin-1 (a ferroptosis inhibitor) and MitoTEMPO, a mitochondrial free radical scavenger, Sal pretreatment effectively alleviated Fe2+ accumulation, redox disequilibrium and maintained mitochondrial energy production and function in I/R-induced myocardial injury, as demonstrated using multifunctional, enzymatic, and morphological indices. However, these effects were abolished by downregulation of AMPKα2 using an adenovirus, both in vivo and in vitro. Moreover, the results also provided a non-canonical mechanism that, under mild mitochondrial ROS generation, Sal pretreatment upregulated and phosphorylated AMPKα2, which enhanced mitochondrial complex I activity to activate innate adaptive responses and increase cellular tolerance to A/R injury.
CONCLUSION: Overall, our work highlighted mitochondria are of great impotance in myocardial I/R-induced ferroptosis and demonstrated that Sal pretreatment activated AMPKα2 against I/R injury, indicating that Sal could become a candidate phytochemical for the treatment of myocardial I/R injury.
Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.